QPX 2014/QPX 7728
Alternative Names: QPX 7728/QPX 2014; QPX2014/QPX7728; QPX2014/QPX7728 FDCLatest Information Update: 28 Dec 2024
At a glance
- Originator The Medicines Company
- Developer Biomedical Advanced Research and Development Authority; Qpex Biopharma
- Class Antibacterials
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in USA (IV)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in Australia (IV)
- 31 Aug 2022 Qpex Biopharma completes a phase I trial in in Bacterial infections (In volunteers) in Australia, USA (IV) (NCT04380207)